Literature DB >> 22505517

One round of SELEX for the generation of DNA aptamers directed against KLK6.

Steve Arnold1, Georgios Pampalakis, Kalliopi Kantiotou, Dilson Silva, Celia Cortez, Sotiris Missailidis, Georgia Sotiropoulou.   

Abstract

Kallikrein-related peptidase 6 (KLK6) is an active serine protease that has been implicated in common pathologies, including neurodegenerative disorders such as Parkinson and Alzheimer disease and certain types of cancer. Antibodies, either polyclonal or monoclonal, that exhibit specificity for distinct members of the extended kallikrein family, including KLK6, were developed. With the exception of KLK3/PSA, the identification and generation of aptamers, as potential new tools with improved characteristics demanded for therapeutic and diagnostic applications, has not been explored for KLKs. Here, we report for the first time the identification of novel DNA aptamers against KLK6 that were isolated using a modified systemic evolution of ligands by exponential enrichment technique. The identified aptamers were characterized using fluorescence spectroscopy, competition ELISA, and quartz crystal microbalance, and two aptamers (008 and 022) were found to exhibit high affinity (K(d) in the low nanomolar range) for KLK6. Aptamers were tested for their ability to bind to serum albumin, to demonstrate their specificity for their target, and the possible involvement of such proteins in the transport of aptamers into the bloodstream. The developed aptamers are expected to assist the development of novel diagnostic, biosensing, and therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22505517     DOI: 10.1515/hsz-2011-0253

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  6 in total

1.  Locked nucleic acid and aptamers.

Authors:  Kasper K Karlsen; Jesper Wengel
Journal:  Nucleic Acid Ther       Date:  2012-12       Impact factor: 5.486

2.  Anti-heparanase aptamers as potential diagnostic and therapeutic agents for oral cancer.

Authors:  Suzanne C Simmons; Hannaleena Jämsä; Dilson Silva; Celia M Cortez; Edward A McKenzie; Carolina C Bitu; Sirpa Salo; Sini Nurmenniemi; Pia Nyberg; Juha Risteli; Carlos E B deAlmeida; Paul E C Brenchley; Tuula Salo; Sotiris Missailidis
Journal:  PLoS One       Date:  2014-10-08       Impact factor: 3.240

3.  Circular and linear: a tale of aptamer selection for the activation of SIRT1 to induce death in cancer cells.

Authors:  Basma Al-Sudani; Abby H Ragazzon-Smith; Athar Aziz; Rania Alansari; Natalie Ferry; Marija Krstic-Demonacos; Patricia A Ragazzon
Journal:  RSC Adv       Date:  2020-12-21       Impact factor: 4.036

4.  Single-step selection of bivalent aptamers validated by comparison with SELEX using high-throughput sequencing.

Authors:  Robert Wilson; Christian Bourne; Roy R Chaudhuri; Richard Gregory; John Kenny; Andrew Cossins
Journal:  PLoS One       Date:  2014-06-25       Impact factor: 3.240

5.  New Technologies Provide Quantum Changes in the Scale, Speed, and Success of SELEX Methods and Aptamer Characterization.

Authors:  Abdullah Ozer; John M Pagano; John T Lis
Journal:  Mol Ther Nucleic Acids       Date:  2014-08-05       Impact factor: 10.183

Review 6.  Aptamer: A potential oligonucleotide nanomedicine in the diagnosis and treatment of hepatocellular carcinoma.

Authors:  Rusdina Bte Ladju; Devis Pascut; Muhammad Nasrum Massi; Claudio Tiribelli; Caecilia H C Sukowati
Journal:  Oncotarget       Date:  2017-12-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.